Alexza Pharmaceuticals, Inc. Inks Deal with Biovail Laboratories Inc. for Anti-Psychotic Drug; Alexza to Get $40 Million Upfront

Reuters -- Alexza Pharmaceuticals Inc said it signed a collaboration deal with a unit of Biovail Corp (BVF.TO) (BVF.N) to develop and commercialize AZ-004, its inhaled treatment for agitation, in the United States and Canada.